MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

MBX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

MBX Biosciences, Inc. Common StockNASDAQ: MBX

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $32.05M rose 66.3% year over year, ahead of the +35.7% change in trailing-twelve-month research & development. Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at +54.7% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +66.3% holds above the trailing-twelve-month pace of +35.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$32.05M+3.4% QoQ
Last fiscal yearDec 2025
$79.16M+37.9% YoY
LTMSep 2026
$101.27M+35.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+66.3%——
1 year+37.9%——
3-year CAGR+54.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
79.16M USD
Year-over-year change
+37.9%
3-year CAGR
+54.7%

Research & Development vs competitors

How MBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +35.7% is the 2nd highest of 8, against a peer median of -10.0%.
  • Over three fiscal years its annual growth of +54.7% compares with a peer median of -0.4%.
MBX Competitors
Research & Development for MBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VKTXViking Therapeutics, Inc.LTM Jun 2026$509.32M USD+227.9%+85.3%—
ASNDAscendis Pharma A/SLTM Sep 2026€274.3M EUR-10.0%-9.3%22.7%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$179.67M USD+7.9%+15.5%64.0%
KLRAKailera Therapeutics, Inc.FY2025$109.11M USD———
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$101.27M USD+35.7%+54.7%—
ALTAltimmune, Inc.LTM Mar 2026$66.77M USD-12.8%-2.0%185483.3%
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M USD-55.0%-0.4%—
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$32.2M USD+26.3%+14.1%10.2%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$5.77M USD-21.5%-38.7%—
Peer median (excluding MBX) —-10.0%-0.4%43.3%

Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue000248K
Gross Profit000(248K)
Gross Margin————
Research & Development21.4M28.53M57.42M79.16M
Selling, General & Admin3.76M6.78M10.78M18.9M
Operating Expenses25.16M35.31M68.19M98.06M
Depreciation & Amortization56K157K244K248K
EBITDA(25.71M)(32.41M)(61.68M)(86.72M)
EBITDA Margin————
Operating Income(25.16M)(35.31M)(68.19M)(98.06M)
Operating Margin————
Interest Income372K2.75M6.27M11.08M
Interest Expense374K000
Other Income / Expenses(974K)2.75M6.27M11.08M
Income Before Tax(26.14M)(32.56M)(61.92M)(86.97M)
Pre-Tax Margin————
Income Tax Expense0000
Net Income(26.14M)(32.56M)(61.92M)(86.97M)
Net Margin————
EPS (Basic)(0.82)(1.02)(1.85)(2.38)
EPS (Diluted)(0.82)(1.02)(1.85)(2.38)
Weighted Avg Shares31.85M31.85M33.39M36.51M
Weighted Avg Shares (Diluted)31.85M31.85M33.39M36.51M

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Intrinsic Alpha fair value

Locked

Current Price

$53.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.